These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 24088065

  • 1. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
    Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M.
    Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
    [Abstract] [Full Text] [Related]

  • 2. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [Abstract] [Full Text] [Related]

  • 3. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 4. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 5. Emerging protein kinase inhibitors for non-small cell lung cancer.
    Liu SV, Subramaniam D, Cyriac GC, Abdul-Khalek FJ, Giaccone G.
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
    [Abstract] [Full Text] [Related]

  • 6. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
    Rolfo C, Passiglia F, Russo A, Pauwels P.
    Expert Opin Ther Targets; 2014 Sep; 18(9):983-5. PubMed ID: 24998601
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM, Rudin CM.
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L.
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [Abstract] [Full Text] [Related]

  • 15. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
    Califano R, Abidin A, Tariq NU, Economopoulou P, Metro G, Mountzios G.
    Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
    [Abstract] [Full Text] [Related]

  • 16. Emerging drugs for squamous cell lung cancer.
    Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R.
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
    [Abstract] [Full Text] [Related]

  • 17. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M, Kojima H, Saito N, Okabe T, Masuda Y, Furuya T, Nagano T.
    Bioorg Med Chem; 2011 May 15; 19(10):3086-95. PubMed ID: 21515061
    [Abstract] [Full Text] [Related]

  • 18. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.
    Cancer Treat Rev; 2013 Dec 15; 39(8):839-50. PubMed ID: 23768755
    [Abstract] [Full Text] [Related]

  • 19. The tissue is the issue: personalized medicine for non-small cell lung cancer.
    Hirsch FR, Wynes MW, Gandara DR, Bunn PA.
    Clin Cancer Res; 2010 Oct 15; 16(20):4909-11. PubMed ID: 20926402
    [Abstract] [Full Text] [Related]

  • 20. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb 15; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.